WHIPPANY, N.J., July 22, 2019 /PRNewswire/ -- In response to
the report in today's Annals of Internal Medicine, Bayer
realizes there may be confusion around the appropriate use of
aspirin, which in the United
States is only approved for secondary prevention. Aspirin is
not appropriate for everyone, so patients should talk to their
doctor before they begin an aspirin regimen.
This report only looked at patients who take aspirin for primary
prevention, which is the use of aspirin to prevent a first
cardiovascular event, such as a heart attack or ischemic
stroke. Importantly, it did not look at patients who take
aspirin for secondary prevention, which is when someone takes
aspirin because they already have known underlying risk of
cardiovascular disease and are trying to prevent another event.
Neither this research nor recent guidelines have changed the
importance of aspirin for these patients. Aspirin continues to be a
life-saving preventative treatment for many patients who have
already had a cardiovascular event.
Bayer reiterates the conclusion of the paper: no one should
start, stop or modify an aspirin regimen without first speaking
with their doctor. The risks of discontinuing an aspirin regimen
are significant – increasing risk for another heart attack by 63
percent and by 40 percent for a clot-related stroke. It is
therefore important that patients speak with their doctor if they
have any questions about recent news or research regarding aspirin.
About Bayer
Bayer is a global enterprise with core
competencies in the life science fields of health care and
nutrition. Its products and services are designed to benefit people
by supporting efforts to overcome the major challenges presented by
a growing and aging global population. At the same time, the Group
aims to increase its earning power and create value through
innovation and growth. Bayer is committed to the principles of
sustainable development, and the Bayer brand stands for trust,
reliability and quality throughout the world. In fiscal 2018, the
Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted
to 2.6 billion euros, R&D
expenses to 5.2 billion euros. For
more information, go to www.bayer.com.
Contacts:
Jennifer Kaczmarek, phone +1
(862) 404-6314
Email:
jennifer.kaczmarek@bayer.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/daily-aspirin-still-recommended-for-millions-of-americans-who-have-had-a-heart-attack-or-ischemic-stroke-300889137.html
SOURCE Bayer